Free preview
LAQ Comprehensive
MD Pharmacology NMC syllabus Full notes Recent advances last updated on 2026-06-22

H1 Antihistamines

H₁-Receptor Antagonists (Inverse Agonists) — First- vs Second-Generation Classification, Mechanism, Pharmacokinetics, Clinical Uses & Adverse Effects

Past RGUHS + DNB + MPMSU + MUHS · 4 MPMSUMay '18 MUHSSummer '15 DNBDec '13 RGUHSSep '06

H1 Antihistamines (H1-Receptor Antagonists)

1. Definition, scope & historical context

  • H1 antihistamines are drugs that competitively antagonise the actions of histamine at the H1 receptor; conventionally called "antihistaminics," they are the classical antiallergic agents (G&G 14e Ch.43, p.861; KDT 8e Ch.11, p.178).
  • Histamine is a biogenic amine autacoid (β-imidazolylethylamine) — a "local hormone" produced by diverse cells, intensely bioactive, acting locally at the site of synthesis/release; it is the prototype amine autacoid alongside 5-HT (KDT 8e Ch.11, pp.173–4).
  • Histamine acts through four GPCR subtypes (H1–H4); H1 antihistamines are selective for H1 and have negligible potency at H2 and little at H3 (Katzung 16e Ch.16, p.292; G&G 14e Ch.43, p.859).
  • Therapeutic rationale: H1 antagonists suppress the histamine-attributable component of immediate (type I) hypersensitivity — itch, wheal, flare, urticaria, rhinorrhoea, conjunctival symptoms — but do not suppress the antigen–antibody reaction itself (palliative, not curative) (KDT 8e Ch.11, p.182; G&G 14e Ch.43, p.863).
  • Historical milestones:
    • Antihistamine activity first demonstrated by Bovet and Staub in 1937; the first compound protected guinea pigs against lethal histamine but was too toxic for clinical use (G&G 14e Ch.43, p.861).
    • By 1944 Bovet's group described pyrilamine (mepyramine) maleate, the first clinically effective H1 antagonist; diphenhydramine and tripelennamine followed (G&G 14e Ch.43, p.861).
    • First-generation agents introduced from the late 1930s; second-generation (less/non-sedating) agents added after 1980 (KDT 8e Ch.11, pp.178, 181).
    • Histaminergic receptors classified into H1 and H2 by Ash and Schild (1966); Sir James Black (1972) produced the first H2 blocker (burimamide), confirming the classification, and shared the 1988 Nobel Prize (with Elion and Hitchings) (KDT 8e Ch.11, p.174; G&G 14e Ch.43, p.861).
    • H3 receptor identified 1983 (autoreceptor); H4 receptor revealed by molecular cloning in 2001 (KDT 8e Ch.11, p.174).
Continue reading

Antihistamines H1 Antagonists

PharmaNotes Pro · Comprehensive

Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.